Entrada Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Entrada Therapeutics, Inc. (TRDA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TRDA insiders buying or selling?
In the last 12 months, Entrada Therapeutics, Inc. insiders reported 3 open-market purchases ($1.6M) and 21 sales ($15.1M) — net selling of $13.5M. Since November 2021, Trabud has recorded 122 Form 4 filings for TRDA: 20 buys ($40.0M) and 102 sells ($25.9M).
Source: SEC EDGAR Form 4
Key Statistics (November 2021 – Sep 9, 2026)
Total Form 4 filings
122
SEC EDGAR
Insider filers
15
Insider buys (20)
$40.0M
Insider sells (102)
$25.9M
Insider sentiment
Net buyingNet insider flow of $14.2M in net buying since November 2021, and $13.5M in net selling over the last 12 months.
Recent TRDA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 9, 2026 | MPM BIOVENTURES 2018, L.P. | 10% Owner | Sale | 259.8K | $7.33 | $1.9M | SEC ↗ |
| Sep 9, 2026 | MPM BioVentures 2014, L.P. | 10% Owner | Sale | 259.8K | $7.33 | $1.9M | SEC ↗ |
| Sep 3, 2026 | MPM BIOVENTURES 2018, L.P. | 10% Owner | Sale | 86.5K | $7.14 | $617.4K | SEC ↗ |
| Sep 3, 2026 | MPM BioVentures 2014, L.P. | 10% Owner | Sale | 86.5K | $7.14 | $617.4K | SEC ↗ |
| Aug 31, 2026 | MPM BIOVENTURES 2018, L.P. | 10% Owner | Sale | 86.9K | $7.08 | $615.8K | SEC ↗ |
| Aug 31, 2026 | MPM BioVentures 2014, L.P. | 10% Owner | Sale | 86.9K | $7.08 | $615.8K | SEC ↗ |
| Aug 27, 2026 | MPM BioVentures 2014, L.P. | 10% Owner | Sale | 62.7K | $7.36 | $461.5K | SEC ↗ |
| Aug 27, 2026 | MPM BIOVENTURES 2018, L.P. | 10% Owner | Sale | 62.7K | $7.36 | $461.5K | SEC ↗ |
| Aug 10, 2026 | Kush Parmar | Director | Sale | 155.3K | $6.95 | $1.1M | SEC ↗ |
| Aug 10, 2026 | Scott M Rocklage | 10% Owner | Sale | 62.8K | $6.88 | $431.8K | SEC ↗ |
| Aug 3, 2026 | Scott M Rocklage | 10% Owner | Sale | 116.5K | $6.93 | $807.0K | SEC ↗ |
| Aug 3, 2026 | Kush Parmar | Director, 10% Owner | Sale | 116.5K | $6.93 | $807.0K | SEC ↗ |
| May 21, 2026 | Bernhardt G Zeiher | Director | Purchase | 5.0K | $5.86 | $29.3K | SEC ↗ |
| May 4, 2026 | Natarajan Sethuraman | President, Research & Develop. | Sale | 25.9K | $15.39 | $398.8K | SEC ↗ |
| May 4, 2026 | Nathan J Dowden | President & COO | Sale | 15.0K | $15.33 | $230.0K | SEC ↗ |
| Apr 2, 2026 | Kory James Wentworth | Chief Financial Officer | Sale | 2.5K | $12.95 | $32.4K | SEC ↗ |
| Mar 11, 2026 | Nathan J Dowden | President & COO | Sale | 15.0K | $13.04 | $195.8K | SEC ↗ |
| Mar 11, 2026 | Kory James Wentworth | Chief Financial Officer | Sale | 16.5K | $13.01 | $214.4K | SEC ↗ |
| Mar 6, 2026 | Kory James Wentworth | Chief Financial Officer | Sale | 8.0K | $12.25 | $97.9K | SEC ↗ |
| Nov 24, 2025 | Kory James Wentworth | Chief Financial Officer | Sale | 8.9K | $9.98 | $88.9K | SEC ↗ |
| Nov 24, 2025 | Felix Baker | 10% Owner | Purchase | 28.9K | $9.07 | $261.8K | SEC ↗ |
| Nov 18, 2025 | Kush Parmar | Director, 10% Owner | Sale | 200.0K | $8.80 | $1.8M | SEC ↗ |
| Nov 18, 2025 | Scott M Rocklage | 10% Owner | Sale | 200.0K | $8.80 | $1.8M | SEC ↗ |
| Nov 12, 2025 | Felix Baker | 10% Owner | Purchase | 178.0K | $7.60 | $1.4M | SEC ↗ |
| Jul 11, 2025 | Kush Parmar | Director, 10% Owner | Sale | 27.0K | $7.50 | $202.6K | SEC ↗ |
Showing the 25 most recent of 122 Form 4 filings for Entrada Therapeutics, Inc..
Most active TRDA insiders
- Dipal Doshi25 filings
- Kory James Wentworth21 filings
- Nathan J Dowden17 filings
- Natarajan Sethuraman10 filings
- Nerissa Kreher9 filings
Ask anything about TRDA insider activity
Use Trabud's AI agent to query Entrada Therapeutics, Inc.'s Form 4 history in plain English — "Show me TRDA CEO purchases this year" or compare it against any other ticker.
Open the AI agentTRDA insider trading FAQ
Are Entrada Therapeutics, Inc. insiders buying or selling?
In the last 12 months, Entrada Therapeutics, Inc. insiders reported 3 open-market purchases ($1.6M) and 21 sales ($15.1M) — net selling of $13.5M. Since November 2021, Trabud has recorded 122 Form 4 filings for TRDA: 20 buys ($40.0M) and 102 sells ($25.9M). Over the full record that is net buying of $14.2M.
How many insiders trade TRDA stock?
15 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Entrada Therapeutics, Inc.. The most recent filing was accepted on Sep 9, 2026.
Where does Trabud get TRDA insider trading data?
All TRDA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.